Home Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

FPG #8: Alternative Treatments in Psychiatry
FPG #7: Critical Care in Neurology
Free Medical Books

  Hepatitis C

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 283 articles:
HTML format
Text format



Single Articles


    February 2012
  1. SCULL MA , Ploss A
    Exiting from uncharted territory: Hepatitis C virus assembles in mouse cell lines.
    Hepatology. 2012;55:645-8.
    PubMed     Text format     Related articles   



    January 2012
  2. SCHOLTES C , Ramiere C, Rainteau D, Perrin-Cocon L, et al
    High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients.
    Hepatology. 2012 Jan 30. doi: 10.1002/hep.25628.
    PubMed     Text format     Related articles    Abstract available



  3. MERCHANTE N , Rivero-Juarez A, Tellez F, Merino D, et al
    Liver stiffness predicts clinical outcome in HIV/HCV-coinfected patients with compensated liver cirrhosis.
    Hepatology. 2012 Jan 25. doi: 10.1002/hep.25616.
    PubMed     Text format     Related articles    Abstract available



  4. RASMUSSEN AL , Tchitchek N, Susnow NJ, Krasnoselsky AL, et al
    Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.
    Hepatology. 2012 Jan 25. doi: 10.1002/hep.25612.
    PubMed     Text format     Related articles    Abstract available



  5. D'AMBROSIO R , Aghemo A, Grazia Rumi M, Ronchi G, et al
    A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients.
    Hepatology. 2012 Jan 23. doi: 10.1002/hep.25606.
    PubMed     Text format     Related articles    Abstract available



  6. REMBECK K , Westin J, Lindh M, Hellstrand K, et al
    Association between IL28B-related genetic variants and liver histopathology differs between hcv genotypes.
    Hepatology. 2012 Jan 23. doi: 10.1002/hep.25598.
    PubMed     Text format     Related articles   



  7. FISCHER J , Bohm S, Scholz M, Muller T, et al
    Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection.
    Hepatology. 2012 Jan 11. doi: 10.1002/hep.25582.
    PubMed     Text format     Related articles    Abstract available



  8. SUN JH , O' Boyle Ii DR, Zhang Y, Wang C, et al
    Impact of a baseline polymorphism on the emergence of resistance to the HCV NS5A replication complex inhibitor BMS-790052.
    Hepatology. 2012 Jan 11. doi: 10.1002/hep.25581.
    PubMed     Text format     Related articles    Abstract available



  9. LIU L , Fisher BE, Thomas DL, Cox AL, et al
    Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.
    Hepatology. 2012 Jan 11. doi: 10.1002/hep.25575.
    PubMed     Text format     Related articles    Abstract available



    December 2011
  10. PAN Q , de Ruiter PE, Metselaar HJ, Kwekkeboom J, et al
    Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo.
    Hepatology. 2011 Dec 27. doi: 10.1002/hep.25562.
    PubMed     Text format     Related articles    Abstract available



  11. DENNISTON MM , Monina KR, McQuillan GM, Jiles RB, et al
    Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: NHANES 2001-08.
    Hepatology. 2011 Dec 27. doi: 10.1002/hep.25556.
    PubMed     Text format     Related articles    Abstract available



  12. ROWE I , Armstrong M, Houlihan D
    Prioritising treatment experienced patients with hepatitis C infection for treatment with telaprevir: A number needed to treat approach.
    Hepatology. 2011 Dec 27. doi: 10.1002/hep.25553.
    PubMed     Text format     Related articles   



  13. PEARLMAN BL , Ehleben C
    Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a/ribavirin.
    Hepatology. 2011 Dec 27. doi: 10.1002/hep.25552.
    PubMed     Text format     Related articles   



  14. REDDY SK , Steel JL, Chen HW, Demateo DJ, et al
    Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Hepatology. 2011 Dec 20. doi: 10.1002/hep.25536.
    PubMed     Text format     Related articles    Abstract available



  15. KHACHATOORIAN R , Arumugaswami V, Ruchala P, Raychaudhuri S, et al
    A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A mediated translation and virus production.
    Hepatology. 2011 Dec 20. doi: 10.1002/hep.25533.
    PubMed     Text format     Related articles    Abstract available



  16. DIETERICH D
    The end of the beginning for hepatitis C treatment.
    Hepatology. 2011 Dec 16. doi: 10.1002/hep.25528.
    PubMed     Text format     Related articles   



  17. SEBASTIANI G , Alberti A
    Diagnostic algorithms for liver fibrosis in hepatitis C: Are they ready to avoid liver biopsy?
    Hepatology. 2011 Dec 12. doi: 10.1002/hep.25517.
    PubMed     Text format     Related articles   



  18. COBB B , Vilchez RA
    An update on treatment of HCV genotype 1 infection and viral load assessments.
    Hepatology. 2011 Dec 12. doi: 10.1002/hep.25516.
    PubMed     Text format     Related articles   



  19. GHANY MG , Nelson DR, Strader DB, Thomas DL, et al
    Re: HEP-11-1628 - An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the american association for the study of liver diseases.
    Hepatology. 2011 Dec 12. doi: 10.1002/hep.25524.
    PubMed     Text format     Related articles   



  20. QUARATO G , D'Aprile A, Gavillet B, Vuagniaux G, et al
    The cyclophilin inhibitor alisporivir prevents hepatitis C virus- mediated mitochondrial dysfunction.
    Hepatology. 2011 Dec 2. doi: 10.1002/hep.25514.
    PubMed     Text format     Related articles    Abstract available



  21. MCGARRY LJ , Pawar VS, Parekh HH, Rubin JL, et al
    Economic model of a birth cohort screening program for hepatitis C virus.
    Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510.
    PubMed     Text format     Related articles    Abstract available



  22. PETTA S , Torres D, Fazio G, Camma C, et al
    Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations.
    Hepatology. 2011 Dec 2. doi: 10.1002/hep.25508.
    PubMed     Text format     Related articles    Abstract available



  23. ANDRUS L , Marukian S, Jones CT, Catanese MT, et al
    Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells.
    Hepatology. 2011;54:1901-12.
    PubMed     Text format     Related articles    Abstract available



  24. GREBELY J , Dore GJ
    An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community.
    Hepatology. 2011;54:2259-61.
    PubMed     Text format     Related articles   



    November 2011
  25. ALBECKA A , Belouzard S, de Beeck AO, Descamps V, et al
    Role of LDL receptor in the hepatitis c virus life cycle.
    Hepatology. 2011 Nov 26. doi: 10.1002/hep.25501.
    PubMed     Text format     Related articles    Abstract available



  26. HARTRIDGE-LAMBERT SK , Stein EM, Markowitz AJ, Portlock CS, et al
    Hepatitis C and non-Hodgkin lymphoma: The clinical perspective.
    Hepatology. 2011 Nov 26. doi: 10.1002/hep.25499.
    PubMed     Text format     Related articles    Abstract available



  27. CALLAND N , Albecka A, Belouzard S, Wychowski C, et al
    (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Hepatology. 2011 Nov 22. doi: 10.1002/hep.24803.
    PubMed     Text format     Related articles    Abstract available



  28. LANGE CM , Kutalik Z, Morikawa K, Bibert S, et al
    Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Hepatology. 2011 Nov 16. doi: 10.1002/hep.24787.
    PubMed     Text format     Related articles    Abstract available



  29. HARRINGTON PR , Zeng W, Naeger LK
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
    Hepatology. 2011 Nov 16. doi: 10.1002/hep.24791.
    PubMed     Text format     Related articles    Abstract available



  30. GUEDJ J , Dahari H, Shudo E, Smith P, et al
    Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
    Hepatology. 2011 Nov 16. doi: 10.1002/hep.24788.
    PubMed     Text format     Related articles    Abstract available



  31. INNES HA , Hutchinson SJ, Allen S, Bhattacharyya D, et al
    Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
    Hepatology. 2011;54:1547-1558.
    PubMed     Text format     Related articles    Abstract available



  32. MUIR AJ , Poordad FF, McHutchison JG, Shiffman ML, et al
    Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
    Hepatology. 2011;54:1538-46.
    PubMed     Text format     Related articles    Abstract available



  33. GHANY MG , Kim HY, Stoddard A, Wright EC, et al
    Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.
    Hepatology. 2011;54:1527-1537.
    PubMed     Text format     Related articles    Abstract available



  34. HELBIG KJ , Eyre NS, Yip E, Narayana S, et al
    The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A.
    Hepatology. 2011;54:1506-17.
    PubMed     Text format     Related articles    Abstract available



  35. CHARLTON M
    Boceprevir (Victrelis) for HCV: V is for victory and very complex.
    Hepatology. 2011;54:1882-6.
    PubMed     Text format     Related articles   



  36. WOOD NA , Linn ML, Bowen DG
    Exhausted or just sleeping: Awakening virus-specific responses in chronic hepatitis C virus infection.
    Hepatology. 2011;54:1879-82.
    PubMed     Text format     Related articles   



  37. GORRELL MD , Zekry A, McCaughan GW, Lloyd A, et al
    The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection.
    Hepatology. 2011;54:1875-9.
    PubMed     Text format     Related articles   



  38. ZEISEL MB , Da Costa D, Baumert TF
    Opening the door for hepatitis C virus infection in genetically humanized mice.
    Hepatology. 2011;54:1873-5.
    PubMed     Text format     Related articles   



    October 2011
  39. GREBELY J , Pham ST, Matthews GV, Petoumenos K, et al
    Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
    Hepatology. 2011 Oct 26. doi: 10.1002/hep.24754.
    PubMed     Text format     Related articles    Abstract available



  40. EVERSON GT , Shiffman ML, Hoefs JC, Morgan TR, et al
    Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial.
    Hepatology. 2011 Oct 26. doi: 10.1002/hep.24752.
    PubMed     Text format     Related articles    Abstract available



  41. LI K , Li NL, Wei D, Pfeffer SR, et al
    Activation of chemokine and inflammatory cytokine response in HCV-infected hepatocytes depends on TLR3 sensing of HCV dsRNA intermediates.
    Hepatology. 2011 Oct 26. doi: 10.1002/hep.24763.
    PubMed     Text format     Related articles    Abstract available



  42. ZEUZEM S , Buggisch P, Agarwal K, Marcellin P, et al
    The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C.
    Hepatology. 2011 Oct 17. doi: 10.1002/hep.24744.
    PubMed     Text format     Related articles    Abstract available



  43. CHAYAMA K , Takahashi S, Toyota J, Karino Y, et al
    Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders.
    Hepatology. 2011 Oct 10. doi: 10.1002/hep.24724.
    PubMed     Text format     Related articles    Abstract available



  44. MCCARTNEY EM , Eyre NS, Beard MR
    Border patrol intensifies for hepatitis C virus entry.
    Hepatology. 2011;54:1472-5.
    PubMed     Text format     Related articles   



  45. RINELLA ME
    Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?
    Hepatology. 2011;54:1118-20.
    PubMed     Text format     Related articles   



  46. NEUMANN-HAEFELIN C , Oniangue-Ndza C, Kuntzen T, Schmidt J, et al
    Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.
    Hepatology. 2011;54:1157-66.
    PubMed     Text format     Related articles    Abstract available



    September 2011
  47. MEULEMAN P , Catanese MT, Verhoye L, Desombere I, et al
    A human monoclonal antibody targeting SR-BI precludes hepatitis C virus infection and viral spread in vitro and in vivo.
    Hepatology. 2011 Sep 27. doi: 10.1002/hep.24692.
    PubMed     Text format     Related articles    Abstract available



  48. TACKE R , Lee HC, Goh C, Courtney J, et al
    Myeloid suppressor cells induced by hepatitis C virus suppress T cell responses through the production of reactive oxygen species.
    Hepatology. 2011 Sep 27. doi: 10.1002/hep.24700.
    PubMed     Text format     Related articles    Abstract available



  49. DE NICOLA S , Aghemo A, Rumi MG, Galmozzi E, et al
    An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis c genotype 4.
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24683.
    PubMed     Text format     Related articles    Abstract available



  50. AMET T , Ghabril M, Chalasani N, Byrd D, et al
    CD59 incorporation protects hepatitis C virus against complement-mediated destruction.
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24686.
    PubMed     Text format     Related articles    Abstract available



  51. SANDRA B , F SA, Karoline R, Judith M, et al
    Treatment of chronic hepatitis C GT 1 patients at an academic center in europe involved in prospective controlled trials - is there a selection bias?
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24671.
    PubMed     Text format     Related articles    Abstract available



  52. DOI H , Iyer TK, Carpenter E, Li H, et al
    Dysfunctional B-cell activation in cirrhosis due to hepatitis C infection associated with disappearance of CD27+ B-cell population.
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24689.
    PubMed     Text format     Related articles    Abstract available



  53. BOCHUD PY , Bibert S, Kutalik Z, Patin E, et al
    IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24678.
    PubMed     Text format     Related articles    Abstract available



  54. WANG MY
    Liver infarction after TIPS in a liver transplant recipient.
    Hepatology. 2011 Sep 19. doi: 10.1002/hep.24672.
    PubMed     Text format     Related articles   



  55. D'AVOLIO A , Ciancio A, Siccardi M, Baietto L, et al
    Ribavirin pharmacokinetics and IL28B plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV 1/4 infected patients.
    Hepatology. 2011 Sep 6. doi: 10.1002/hep.24636.
    PubMed     Text format     Related articles   



  56. MARTIN NK , Vickerman P, Miners A, Foster GR, et al
    The cost-effectiveness of HCV antiviral treatment for injecting drug user populations.
    Hepatology. 2011 Sep 2. doi: 10.1002/hep.24656.
    PubMed     Text format     Related articles    Abstract available



  57. BOURSIER J , de Ledinghen V, Zarski JP, Fouchard-Hubert I, et al
    Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive.
    Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654.
    PubMed     Text format     Related articles    Abstract available



  58. WU C , Gilroy R, Taylor R, Olyaee M, et al
    Alteration of hepatic nuclear receptor-mediated signaling pathways in HCV patients with and without a history of alcohol drinking.
    Hepatology. 2011 Sep 2. doi: 10.1002/hep.24645.
    PubMed     Text format     Related articles    Abstract available



  59. GHANY M , Nelson DR, Strader DB, Thomas DL, et al
    An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the american association for the study of liver diseases.
    Hepatology. 2011 Sep 2. doi: 10.1002/hep.24641.
    PubMed     Text format     Related articles   



  60. LEISE MD , Kim WR, Canterbury KM, Poterucha JJ, et al
    Diagnostic and therapeutic advances in hepatology.
    Hepatology. 2011 Sep 2. doi: 10.1002/hep.24660.
    PubMed     Text format     Related articles   



    August 2011
  61. EDLICH B , Ahlenstiel G, Azpiroz AZ, Stoltzfus J, et al
    Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C.
    Hepatology. 2011 Aug 24. doi: 10.1002/hep.24628.
    PubMed     Text format     Related articles    Abstract available



  62. SYED GH , Siddiqui A
    Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus.
    Hepatology. 2011 Aug 19. doi: 10.1002/hep.24619.
    PubMed     Text format     Related articles    Abstract available



  63. WHITE DL , Tavakoli-Tabasi S, Kuzniarek J, Pascua R, et al
    Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
    Hepatology. 2011 Aug 19. doi: 10.1002/hep.24618.
    PubMed     Text format     Related articles    Abstract available



  64. CIESEK S , von Hahn T, Colpitts CC, Schang LM, et al
    The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entry.
    Hepatology. 2011 Aug 11. doi: 10.1002/hep.24610.
    PubMed     Text format     Related articles    Abstract available



  65. NETTLES RE , Gao M, Bifano M, Chung E, et al
    Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
    Hepatology. 2011 Aug 11. doi: 10.1002/hep.24609.
    PubMed     Text format     Related articles    Abstract available



  66. PARIS AJ , Snapir Z, Christopherson CD, Kwok SY, et al
    A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.
    Hepatology. 2011 Aug 11. doi: 10.1002/hep.24608.
    PubMed     Text format     Related articles    Abstract available



  67. VALENTI L , Fargion S
    PNPLA3 I148M and fibrosis progression after liver transplantation.
    Hepatology. 2011 Aug 11. doi: 10.1002/hep.24601.
    PubMed     Text format     Related articles   



  68. FRIDELL RA , Wang C, Sun JH, O' Boyle DR 2nd, et al
    Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: In Vitro and In Vivo correlations.
    Hepatology. 2011 Aug 1. doi: 10.1002/hep.24594.
    PubMed     Text format     Related articles    Abstract available



    July 2011
  69. MARTINOT-PEIGNOUX M , Asselah T, Marcellin P
    HEP-09-1639.R1 correspondence invitation Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the SVR in patients with HCV receiving PEG-IFN and ribavirin.
    Hepatology. 2011 Jul 28. doi: 10.1002/hep.24585.
    PubMed     Text format     Related articles   



  70. MARUKIAN S , Andrus L, Sheahan TP, Jones CT, et al
    Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures.
    Hepatology. 2011 Jul 28. doi: 10.1002/hep.24580.
    PubMed     Text format     Related articles    Abstract available



  71. CHOI SS , Bradrick S, Qiang G, Mostafavi A, et al
    Upregulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication.
    Hepatology. 2011 Jul 25. doi: 10.1002/hep.24576.
    PubMed     Text format     Related articles    Abstract available



  72. GAL-TANAMY M , Bachmetov L, Ravid A, Koren R, et al
    Vitamin-D: An innate antiviral agent suppressing Hepatitis C virus in human hepatocytes.
    Hepatology. 2011 Jul 25. doi: 10.1002/hep.24575.
    PubMed     Text format     Related articles    Abstract available



  73. DO O NT , Eurich D, Trautwein C, Neuhaus P, et al
    The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C.
    Hepatology. 2011 Jul 11. doi: 10.1002/hep.24535.
    PubMed     Text format     Related articles   



  74. ROCKENBACH G , De Melo Neto AJ, Barcellos NT, Wolff FH, et al
    Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection.
    Hepatology. 2011 Jul 11. doi: 10.1002/hep.24533.
    PubMed     Text format     Related articles   



  75. GOLDEN-MASON L , Bambha KM, Cheng L, Howell CD, et al
    Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.
    Hepatology. 2011 Jul 11. doi: 10.1002/hep.24556.
    PubMed     Text format     Related articles    Abstract available



  76. SCHERZER TM , Friedrich Stattermayer A, Strasser M, Laferl H, et al
    Impact of IL28B on treatment outcome in HCV G1/4 patients receiving response-guided therapy with peginterferon alfa-2a (40KD)/ ribavirin.
    Hepatology. 2011 Jul 11. doi: 10.1002/hep.24546.
    PubMed     Text format     Related articles    Abstract available



  77. MAZUMDAR B , Banerjee A, Meyer K, Ray R, et al
    Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
    Hepatology. 2011 Jul 6. doi: 10.1002/hep.24523.
    PubMed     Text format     Related articles    Abstract available



  78. KANDA T , Imazeki F, Wu S, Nakamoto S, et al
    The assessment of serum HCV RNA 12 weeks after the end of treatment using TaqMan PCR is less relevant than after 24 weeks for predicting SVR.
    Hepatology. 2011 Jul 2. doi: 10.1002/hep.24512.
    PubMed     Text format     Related articles   



  79. LIM LY , Kwo PY
    A glimpse at the future of hepatitis C therapy: The INFORM trial.
    Hepatology. 2011;54:360-3.
    PubMed     Text format     Related articles   



  80. CHARLTON M
    Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
    Hepatology. 2011;54:3-5.
    PubMed     Text format     Related articles   



  81. GARG V , van Heeswijk R, Lee JE, Alves K, et al
    Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
    Hepatology. 2011;54:20-7.
    PubMed     Text format     Related articles    Abstract available



  82. PARK O , Wang H, Weng H, Feigenbaum L, et al
    In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression.
    Hepatology. 2011;54:252-61.
    PubMed     Text format     Related articles    Abstract available



    June 2011
  83. MARABITA F , Aghemo A, De Nicola S, Rumi MG, et al
    Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.
    Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503.
    PubMed     Text format     Related articles    Abstract available



  84. CHEN DS
    Fighting against viral hepatitis: Lessons from Taiwan.
    Hepatology. 2011 Jun 30. doi: 10.1002/hep.24500.
    PubMed     Text format     Related articles    Abstract available



  85. BHALA N , Angulo P, van der Poorten D, Lee E, et al
    The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study.
    Hepatology. 2011 Jun 17. doi: 10.1002/hep.24491.
    PubMed     Text format     Related articles    Abstract available



  86. BARTH H , Rybczynska J, Patient R, Choi Y, et al
    Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
    Hepatology. 2011 Jun 14. doi: 10.1002/hep.24489.
    PubMed     Text format     Related articles    Abstract available



  87. INDOLFI G , Sambrotta M, Moriondo M, Azzari C, et al
    Genetic variation in IL28B locus is associated with spontaneous clearance of HCV in children with Non-1 viral genotype infection.
    Hepatology. 2011 Jun 14. doi: 10.1002/hep.24482.
    PubMed     Text format     Related articles   



  88. DI MARTINO V , Richou C, Cervoni JP, Sanchez-Tapias JM, et al
    Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized controlled trials and implications for the future.
    Hepatology. 2011 Jun 14. doi: 10.1002/hep.24480.
    PubMed     Text format     Related articles    Abstract available



  89. ARONSOHN A , Jensen D
    Distributive justice and the arrival of direct-acting antivirals: who should be first in line?
    Hepatology. 2011;53:1789-91.
    PubMed     Text format     Related articles   



  90. FIORAVANTI J , Gonzalez I, Medina-Echeverz J, Larrea E, et al
    Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.
    Hepatology. 2011;53:1864-73.
    PubMed     Text format     Related articles    Abstract available



    May 2011
  91. PENG ZG , You XF, Jiang JD
    Editing enzyme human APOBEC3G (hA3G) could be a promising therapeutic target for hepatitis C virus (HCV) drug discovery.
    Hepatology. 2011 May 29. doi: 10.1002/hep.24462.
    PubMed     Text format     Related articles   



  92. HIRAGA N , Imamura M, Abe H, Nelson Hayes C, et al
    Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo.
    Hepatology. 2011 May 29. doi: 10.1002/hep.24460.
    PubMed     Text format     Related articles    Abstract available



  93. HIRAGA N , Abe H, Imamura M, Tsuge M, et al
    Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus.
    Hepatology. 2011 May 26. doi: 10.1002/hep.24453.
    PubMed     Text format     Related articles    Abstract available



  94. JI HF
    Vitamin D levels may explain the racial differences in response rates to antiviral therapy of chronic hepatitis C.
    Hepatology. 2011 May 26. doi: 10.1002/hep.24447.
    PubMed     Text format     Related articles   



  95. COPPOLA N , Pisaturo M, Guastafierro S, Tonziello G, et al
    Absence of occult HCV infection in patients under immunosupressive therapy for oncohematological diseases.
    Hepatology. 2011 May 23. doi: 10.1002/hep.24436.
    PubMed     Text format     Related articles   



  96. KALAMBOKIS GN , Tsianos EV
    Raised sympathetic activity and blood ammonia could increase sensitivity to infections in patients with cirrhosis and refractory ascites on beta-blockers.
    Hepatology. 2011 May 23. doi: 10.1002/hep.24439.
    PubMed     Text format     Related articles   



  97. ALISI A , Tomaselli S, Balsano C, Gallo A, et al
    Hepatitis C virus (HCV) therapeutics: Editing enzymes promising therapeutic targets?
    Hepatology. 2011 May 11. doi: 10.1002/hep.24409.
    PubMed     Text format     Related articles   



  98. NGUYEN D , Talwalkar JA
    Diagnostic and therapeutic advances in Hepatology noninvasive assessment of liver fibrosis.
    Hepatology. 2011 May 5. doi: 10.1002/hep.24401.
    PubMed     Text format     Related articles   



  99. DAI CY , Huang CF, Huang JF, Chuang WL, et al
    Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
    Hepatology. 2011;53:1774-5.
    PubMed     Text format     Related articles   



  100. RODRIGUE JR , Balistreri W, Haber B, Jonas MM, et al
    Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.
    Hepatology. 2011;53:1468-75.
    PubMed     Text format     Related articles    Abstract available



    April 2011
  101. SAEED M , Shiina M, Date T, Akazawa D, et al
    In Vivo adaptation of hepatitis C virus for efficient virus production and evasion of apoptosis.
    Hepatology. 2011 Apr 29. doi: 10.1002/hep.24399.
    PubMed     Text format     Related articles   



  102. LAI JC , Verna EC, Brown RS Jr, O'Leary JG, et al
    Hepatitis C virus infected females have a higher risk of advanced fibrosis and graft loss after liver transplantation than males.
    Hepatology. 2011 Apr 28. doi: 10.1002/hep.24390.
    PubMed     Text format     Related articles   



  103. NDONGO-THIAM N , Berthillon P, Errazuriz E, Bordes I, et al
    Long-term propagation of serum hepatitis C virus with production of enveloped HCV particles in human HepaRG hepatocytes.
    Hepatology. 2011 Apr 21. doi: 10.1002/hep.24386.
    PubMed     Text format     Related articles   



  104. RAIMONDO G , Pollicino T, Levrero M, Craxi A, et al
    Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C.
    Hepatology. 2011 Apr 21. doi: 10.1002/hep.24379.
    PubMed     Text format     Related articles   



  105. FOSTER TL , Verow M, Wozniak AL, Bentham MJ, et al
    Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus (HCV) p7 ion channel.
    Hepatology. 2011 Apr 21. doi: 10.1002/hep.24371.
    PubMed     Text format     Related articles   



  106. DIENSTAG JL , Ghany MG, Morgan TR, Di Bisceglie AM, et al
    A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210).
    Hepatology. 2011 Apr 21. doi: 10.1002/hep.24370.
    PubMed     Text format     Related articles   



  107. EHRHARDT M , Leidinger P, Keller A, Baumert TF, et al
    Profound differences of miRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in HCV studies.
    Hepatology. 2011 Apr 18. doi: 10.1002/hep.24366.
    PubMed     Text format     Related articles   



  108. MELIA MT , Muir AJ, McCone J, Shiffman ML, et al
    Racial differences in hepatitis C treatment eligibility.
    Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358.
    PubMed     Text format     Related articles    Abstract available



  109. TREPO E , Pradat P, Potthoff A, Momozawa Y, et al
    Impact of PNPLA3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.
    Hepatology. 2011 Apr 12. doi: 10.1002/hep.24350.
    PubMed     Text format     Related articles    Abstract available



  110. WAGNER F , Thompson R, Kantaridis C, Simpson P, et al
    Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1 infected patients.
    Hepatology. 2011 Apr 12. doi: 10.1002/hep.24342.
    PubMed     Text format     Related articles    Abstract available



  111. CLEMENT S , Peyrou M, Sanchez-Pareja A, Bourgoin L, et al
    Downregulation of PTEN and IRS-1 by HCV 3a core protein triggers the formation of large lipid droplets in hepatocytes.
    Hepatology. 2011 Apr 4. doi: 10.1002/hep.24340.
    PubMed     Text format     Related articles    Abstract available



  112. ZUR WIESCH JS , Pudelski N, Hoepner L, Supplieth M, et al
    "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
    Hepatology. 2011;53:1453-4.
    PubMed     Text format     Related articles   



  113. LOFTIS JM , Morasco BJ, Hauser P
    Depression and antiviral response to interferon-based therapy for hepatitis C virus infection.
    Hepatology. 2011;53:1413-4.
    PubMed     Text format     Related articles   



  114. GIANNI T , Paolo B
    Hepatitis C recurrence: Influence of serum cholesterol levels and liver steatosis on antiviral therapy.
    Hepatology. 2011;53:1409-10.
    PubMed     Text format     Related articles   



  115. YU ML
    The importance of the definition of early virological response for predicting treatment efficacy for chronic hepatitis C.
    Hepatology. 2011;53:1403.
    PubMed     Text format     Related articles   



  116. DAI CY , Yeh ML, Huang JF, Chuang WL, et al
    Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier.
    Hepatology. 2011;53:1399.
    PubMed     Text format     Related articles   



  117. PFANNKUCHE A , Buther K, Karthe J, Poenisch M, et al
    C-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: A prerequisite for replication.
    Hepatology. 2011;53:1127-36.
    PubMed     Text format     Related articles    Abstract available



  118. BITETTO D , Fattovich G, Fabris C, Ceriani E, et al
    Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
    Hepatology. 2011;53:1118-26.
    PubMed     Text format     Related articles    Abstract available



  119. SIEVERT W , Dore GJ, McCaughan GW, Yoshihara M, et al
    Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
    Hepatology. 2011;53:1109-1117.
    PubMed     Text format     Related articles    Abstract available



  120. DI BISCEGLIE AM , Stoddard AM, Dienstag JL, Shiffman ML, et al
    Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
    Hepatology. 2011;53:1100-1108.
    PubMed     Text format     Related articles    Abstract available



  121. IMHOF I , Simmonds P
    Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Hepatology. 2011;53:1090-9.
    PubMed     Text format     Related articles    Abstract available



  122. PENG ZG , Zhao ZY, Li YP, Wang YP, et al
    Host apolipoprotein b messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.
    Hepatology. 2011;53:1080-9.
    PubMed     Text format     Related articles    Abstract available



  123. ALBERT ML , Casrouge A, Chevaliez S, Hezode C, et al
    Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype.
    Hepatology. 2011;53:1410-1.
    PubMed     Text format     Related articles   



  124. PAN Q , Tilanus HW, Janssen HL, van der Laan LJ, et al
    Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element.
    Hepatology. 2011;53:1400-1.
    PubMed     Text format     Related articles   



  125. OHISHI W , Fujiwara S, Cologne JB, Suzuki G, et al
    Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma.
    Hepatology. 2011;53:1237-45.
    PubMed     Text format     Related articles    Abstract available



  126. MAKOWSKA Z , Duong FH, Trincucci G, Tough DF, et al
    Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo.
    Hepatology. 2011;53:1154-63.
    PubMed     Text format     Related articles    Abstract available



    March 2011
  127. PETROVIC D , Stamataki Z, Dempsey E, Golden-Mason L, et al
    Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion.
    Hepatology. 2011 Mar 30. doi: 10.1002/hep.24327.
    PubMed     Text format     Related articles    Abstract available



  128. ECHEVERRIA I , Pereboev A, Silva L, Zabaleta A, et al
    Enhanced T-cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
    Hepatology. 2011 Mar 30. doi: 10.1002/hep.24325.
    PubMed     Text format     Related articles    Abstract available



  129. DAHARI H , Guedj J, Perelson AS
    Silibinin mode of action(s) against HCV: A controversy yet to be resolved.
    Hepatology. 2011 Mar 23. doi: 10.1002/hep.24310.
    PubMed     Text format     Related articles   



  130. NGUYEN LH , Ko S, Wong SS, Tran PS, et al
    Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection.
    Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308.
    PubMed     Text format     Related articles    Abstract available



  131. RUIZ-EXTREMERA A , Munoz-Gamez J, Salmeron-Ruiz MA, de Rueda PM, et al
    Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children.
    Hepatology. 2011 Mar 16. doi: 10.1002/hep.24298.
    PubMed     Text format     Related articles    Abstract available



  132. BENSADOUN P , Rodriguez C, Soulier A, Higgs M, et al
    Genetic background of hepatocyte cell lines: Are in vitro hepatitis C virus research data reliable?
    Hepatology. 2011 Mar 7. doi: 10.1002/hep.24278.
    PubMed     Text format     Related articles   



  133. GUEDJ J , Perelson AS
    Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness: Implications for treatment duration.
    Hepatology. 2011 Mar 7. doi: 10.1002/hep.24272.
    PubMed     Text format     Related articles    Abstract available



  134. MOSCHEN AR , Fritz T, Clouston AD, Rebhan I, et al
    IL-32: A new proinflammatory cytokine involved in HCV-related liver inflammation and fibrosis.
    Hepatology. 2011 Mar 4. doi: 10.1002/hep.24285.
    PubMed     Text format     Related articles    Abstract available



  135. PATEL K , Lucas J, Thompson J, Dubois L, et al
    High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.
    Hepatology. 2011 Mar 4. doi: 10.1002/hep.24284.
    PubMed     Text format     Related articles    Abstract available



  136. PAWLOTSKY JM
    Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus.
    Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262.
    PubMed     Text format     Related articles    Abstract available



  137. LOK AS , Everhart JE, Di Bisceglie AM, Kim HY, et al
    Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C.
    Hepatology. 2011 Mar 3. doi: 10.1002/hep.24257.
    PubMed     Text format     Related articles    Abstract available



  138. LAGGING M , Alsio A, Langeland N, Pedersen C, et al
    Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection.
    Hepatology. 2011;53:1067-8.
    PubMed     Text format     Related articles   



  139. AKHAVAN S , Ronsin C, Laperche S, Thibault V, et al
    Genotype 4 hepatitis C virus: Beware of false-negative RNA detection.
    Hepatology. 2011;53:1066-7.
    PubMed     Text format     Related articles   



  140. MATTHEWS GV , Dore GJ
    Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?
    Hepatology. 2011;53:1055-6.
    PubMed     Text format     Related articles   



  141. SCHUSTER C , Lefevre M, Baumert TF
    Triglyceride synthesis and hepatitis C virus production: Identification of a novel host factor as antiviral target.
    Hepatology. 2011;53:1046-8.
    PubMed     Text format     Related articles   



  142. MOGHADDAM A , Melum E, Reinton N, Ring-Larsen H, et al
    IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Hepatology. 2011;53:746-54.
    PubMed     Text format     Related articles    Abstract available



  143. YE LP , Mao XL
    Is achievement of sustained virologic response an independent predictor or a cofactor for the development of esophageal varices?
    Hepatology. 2011;53:1070-1.
    PubMed     Text format     Related articles   



  144. JORGE A M , Hashem B el-S
    Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases.
    Hepatology. 2011;53:1060-1.
    PubMed     Text format     Related articles   



  145. BRUIX J , Sherman M
    Management of hepatocellular carcinoma: An update.
    Hepatology. 2011;53:1020-2.
    PubMed     Text format     Related articles   



  146. WAGNER M , Zollner G, Trauner M
    Nuclear receptors in liver disease.
    Hepatology. 2011;53:1023-34.
    PubMed     Text format     Related articles    Abstract available



    February 2011
  147. VALENTI L , Colombo M, Fargion S
    PNPLA3 genotype and hepatocellular carcinoma in chronic hepatitis C.
    Hepatology. 2011 Feb 28. doi: 10.1002/hep.24265.
    PubMed     Text format     Related articles   



  148. DI IULIO J , Ciuffi A, Fitzmaurice K, Kelleher D, et al
    Estimating the net contribution of IL28B variation to spontaneous hepatitis C virus clearance.
    Hepatology. 2011 Feb 28. doi: 10.1002/hep.24263.
    PubMed     Text format     Related articles    Abstract available



  149. CORRADINI SG , Burza MA, Molinaro A, Romeo S, et al
    Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma.
    Hepatology. 2011 Feb 23. doi: 10.1002/hep.24244.
    PubMed     Text format     Related articles   



  150. FASSIO E , Landeira G, Longo C, Dominguez N, et al
    Risk factors for infection in chronic hepatitis C: A high prevalence of sexual exposure among human immunodeficiency virus-coinfected women.
    Hepatology. 2011 Feb 11. doi: 10.1002/hep.24224.
    PubMed     Text format     Related articles   



  151. MEDERACKE I , Hahn T
    Survival of the fittest: Selection of hepatitis C virus variants during liver graft reinfection.
    Hepatology. 2011;53:705-8.
    PubMed     Text format     Related articles   



  152. BERRES ML , Trautwein C, Schmeding M, Eurich D, et al
    Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Hepatology. 2011;53:596-603.
    PubMed     Text format     Related articles    Abstract available



  153. SHRIVASTAVA S , Raychoudhuri A, Steele R, Ray R, et al
    Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes.
    Hepatology. 2011;53:406-14.
    PubMed     Text format     Related articles    Abstract available



  154. RONGEY C , Yee HF Jr
    From the bedside to the community: comparative effectiveness, health services, and implementation research.
    Hepatology. 2011;53:673-7.
    PubMed     Text format     Related articles   



  155. VIBERT E , Duclos-Vallee JC, Ghigna MR, Hoti E, et al
    Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection.
    Hepatology. 2011;53:475-82.
    PubMed     Text format     Related articles    Abstract available



  156. THOMPSON AJ , Santoro R, Piazzolla V, Clark PJ, et al
    Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
    Hepatology. 2011;53:389-95.
    PubMed     Text format     Related articles    Abstract available



  157. SUZUKI F , Suzuki Y, Akuta N, Sezaki H, et al
    Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Hepatology. 2011;53:415-21.
    PubMed     Text format     Related articles    Abstract available



    January 2011
  158. MEULEMAN P , Bukh J, Verhoye L, Farhoudi A, et al
    In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.
    Hepatology. 2011 Jan 11. doi: 10.1002/hep.24171.
    PubMed     Text format     Related articles    Abstract available



  159. SINGAL AK , Jampana SC, Anand BS
    Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C.
    Hepatology. 2011 Jan 10. doi: 10.1002/hep.24165.
    PubMed     Text format     Related articles   



  160. CHUNG-FENG H , Chia-Yen D, Jee-Fu H, Wan-Long C, et al
    Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients.
    Hepatology. 2011;53:367-8.
    PubMed     Text format     Related articles   



  161. AFDHAL NH , McHutchison JG, Zeuzem S, Mangia A, et al
    Hepatitis C pharmacogenetics: State of the art in 2010.
    Hepatology. 2011;53:336-345.
    PubMed     Text format     Related articles    Abstract available



  162. CHARLTON MR , Thompson A, Veldt BJ, Watt K, et al
    Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.
    Hepatology. 2011;53:317-24.
    PubMed     Text format     Related articles    Abstract available



  163. KRAMER JR , Hachem CY, Kanwal F, Mei M, et al
    Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection.
    Hepatology. 2011;53:42-52.
    PubMed     Text format     Related articles    Abstract available



  164. THOMAS E , Feld JJ, Li Q, Hu Z, et al
    Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
    Hepatology. 2011;53:32-41.
    PubMed     Text format     Related articles    Abstract available



  165. DIAZ-VALDES N , Manterola L, Belsue V, Riezu-Boj JI, et al
    Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.
    Hepatology. 2011;53:23-31.
    PubMed     Text format     Related articles    Abstract available



  166. DARLING JM , Aerssens J, Fanning G, McHutchison JG, et al
    Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
    Hepatology. 2011;53:14-22.
    PubMed     Text format     Related articles    Abstract available



  167. YU ML , Huang CF, Huang JF, Chang NC, et al
    Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
    Hepatology. 2011;53:7-13.
    PubMed     Text format     Related articles    Abstract available



  168. MARTINEZ SM , Crespo G, Navasa M, Forns X, et al
    Noninvasive assessment of liver fibrosis.
    Hepatology. 2011;53:325-35.
    PubMed     Text format     Related articles    Abstract available



  169. LINDOR RA , Lindor KD
    The value of observational research in liver diseases.
    Hepatology. 2011;53:1-3.
    PubMed     Text format     Related articles   



    December 2010
  170. STEPANOVA M , Kanwal F, El-Serag HB, Younossi ZM, et al
    Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States.
    Hepatology. 2010 Dec 17. doi: 10.1002/hep.24131.
    PubMed     Text format     Related articles    Abstract available



  171. MENSA L , Crespo G, Gastinger MJ, Kabat J, et al
    Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics.
    Hepatology. 2010 Dec 14. doi: 10.1002/hep.24110.
    PubMed     Text format     Related articles    Abstract available



  172. YOON SM , Gerasimidou D, Kuwahara R, Hytiroglou P, et al
    Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans.
    Hepatology. 2010 Dec 14. doi: 10.1002/hep.24122.
    PubMed     Text format     Related articles    Abstract available



  173. JUNG KS , Kim SU, Ahn SH, Park YN, et al
    Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).
    Hepatology. 2010 Dec 14. doi: 10.1002/hep.24121.
    PubMed     Text format     Related articles    Abstract available



  174. VALENTI L , Rumi M, Galmozzi E, Aghemo A, et al
    Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.
    Hepatology. 2010 Dec 13. doi: 10.1002/hep.24123.
    PubMed     Text format     Related articles    Abstract available



  175. LIN ZH , Xin YN, Dong QJ, Wang Q, et al
    Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis.
    Hepatology. 2010 Dec 7. doi: 10.1002/hep.24105.
    PubMed     Text format     Related articles    Abstract available



  176. BERRES ML , Trautwein C, Schmeding M, Eurich D, et al
    Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  177. KERSHENOBICH D , Munoz L, Male R, Gaytan J, et al
    Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Hepatology. 2010;52:2240-1.
    PubMed     Text format     Related articles   



  178. GEROLD G , Rice CM, Ploss A
    Teaching new tricks to an old foe: murinizing hepatitis C virus.
    Hepatology. 2010;52:2233-6.
    PubMed     Text format     Related articles    Abstract available



  179. ZHU Z , Wilson AT, Luxon BA, Brown KE, et al
    Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?
    Hepatology. 2010;52:1897-905.
    PubMed     Text format     Related articles    Abstract available



  180. KERSHENOBICH D , Munoz L, Male R, Gaytan J, et al
    Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Hepatology. 2010;52:2240-1.
    PubMed     Text format     Related articles   



  181. GEROLD G , Rice CM, Ploss A
    Teaching new tricks to an old foe: murinizing hepatitis C virus.
    Hepatology. 2010;52:2233-6.
    PubMed     Text format     Related articles    Abstract available



  182. ZHU Z , Wilson AT, Luxon BA, Brown KE, et al
    Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?
    Hepatology. 2010;52:1897-905.
    PubMed     Text format     Related articles    Abstract available



  183. MACARON C , Hanouneh IA, Zein NN
    Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis.
    Hepatology. 2010;52:2240.
    PubMed     Text format     Related articles   



    November 2010
  184. SHRIVASTAVA S , Raychoudhuri A, Steele R, Ray R, et al
    Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  185. MERANI S , Petrovic D, James I, Chopra A, et al
    Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak.
    Hepatology. 2010 Nov 12. doi: 10.1002/hep.24076.
    PubMed     Text format     Related articles    Abstract available



  186. LOFTIS JM , Morasco BJ, Hauser P
    Depression and antiviral response to interferon-based therapy for hepatitis C virus infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  187. LINDH M , Lagging M, Norkrans G, Hellstrand K, et al
    Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection.
    Hepatology. 2010;52:1860-1.
    PubMed     Text format     Related articles   



  188. LAM KD , Trinh HN, Do ST, Nguyen TT, et al
    Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6.
    Hepatology. 2010;52:1573-80.
    PubMed     Text format     Related articles    Abstract available



  189. PHAM ST , Bull RA, Bennett JM, Rawlinson WD, et al
    Frequent multiple hepatitis C virus infections among injection drug users in a prison setting.
    Hepatology. 2010;52:1564-72.
    PubMed     Text format     Related articles    Abstract available



  190. DE MATTOS AZ , de Almeida PR, Tovo CV, de Mattos AA, et al
    Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    Hepatology. 2010;52:1867.
    PubMed     Text format     Related articles   



    October 2010
  191. TESTINO G , Borro P
    Hepatitis C recurrence: Influence of serum cholesterol levels and liver steatosis on antiviral therapy.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  192. KRAMER JR , Hachem CY, Kanwal F, Mei M, et al
    Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  193. PEARLMAN BL , Ehleben C
    Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Hepatology. 2010;52:1519-20.
    PubMed     Text format     Related articles   



  194. KWO PY , Vinayek R
    The next step for taribavirin.
    Hepatology. 2010;52:1185-8.
    PubMed     Text format     Related articles   



    September 2010
  195. BANAUDHA K , Kaliszewski M, Korolnek T, Florea L, et al
    MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  196. KORNEK M , Popov Y, Libermann TA, Afdhal NH, et al
    Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  197. THOMAS E , Feld JJ, Li Q, Hu Z, et al
    Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  198. DIAZ-VALDES N , Manterola L, Belsue V, Riezu-Boj JI, et al
    Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  199. AKHAVAN S , Ronsin C, Laperche S, Thibault V, et al
    Genotype 4 hepatitis C virus: Beware of false-negative RNA detection.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  200. PIROTH L , Larsen C, Binquet C, Alric L, et al
    Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study.
    Hepatology. 2010 Sep 7:1916-1923.
    PubMed     Text format     Related articles    Abstract available



  201. LAGGING M , Alsio A, Langeland N, Pedersen C, et al
    Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  202. THOMPSON AJ , Clark PJ, McHutchison JG
    Hepatitis C virus nonstructural protein 5A inhibitors: Novel target-Now for new trials and new treatment strategies.
    Hepatology. 2010;52:1162-4.
    PubMed     Text format     Related articles   



  203. MANGIA A , Andriulli A
    Optimal dosage of ribavirin.
    Hepatology. 2010;52:1174.
    PubMed     Text format     Related articles   



  204. AGHEMO A , Rumi MG, De Nicola S, Colombo M, et al
    Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Hepatology. 2010;52:1170-1.
    PubMed     Text format     Related articles   



  205. HARRISON SA , Rossaro L, Hu KQ, Patel K, et al
    Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Hepatology. 2010;52:864-74.
    PubMed     Text format     Related articles    Abstract available



    August 2010
  206. CHUNG RT , Poordad FF, Hassanein T, Zhou X, et al
    Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
    Hepatology. 2010 Aug 31:1907-1915.
    PubMed     Text format     Related articles    Abstract available



  207. URBAN TJ , Thompson AJ, Bradrick SS, Fellay J, et al
    IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  208. GOLDEN-MASON L , Cox AL, Randall JA, Cheng L, et al
    Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  209. PURNAK T , Efe C, Beyazit Y, Ozaslan E, et al
    Serum lipid profile and chronic hepatitis C virus.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  210. DE BRUIJNE J , Bergmann JF, Reesink HW, Weegink CJ, et al
    Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  211. YANG X , Haurigot V, Zhou S, Luo G, et al
    Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microrna cluster.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  212. SALAMONE F , Li Volti G
    Targeting heme oxygenase/adiponectin axis for chronic hepatitis C treatment.
    Hepatology. 2010;52:801.
    PubMed     Text format     Related articles   



  213. RIGAMONTI C , Francesca Donato M, Colombo M
    Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation.
    Hepatology. 2010;52:800-1.
    PubMed     Text format     Related articles   



  214. TUYAMA AC , Hong F, Saiman Y, Wang C, et al
    Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: Implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis.
    Hepatology. 2010;52:612-22.
    PubMed     Text format     Related articles    Abstract available



  215. ASAHINA Y , Tsuchiya K, Tamaki N, Hirayama I, et al
    Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
    Hepatology. 2010;52:518-27.
    PubMed     Text format     Related articles    Abstract available



  216. MACHIDA K , Tsukamoto H, Liu JC, Han YP, et al
    c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2010;52:480-92.
    PubMed     Text format     Related articles    Abstract available



  217. WOODHOUSE SD , Narayan R, Latham S, Lee S, et al
    Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro.
    Hepatology. 2010;52:443-53.
    PubMed     Text format     Related articles    Abstract available



  218. SU J , Brook RA, Kleinman NL, Corey-Lisle P, et al
    The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.
    Hepatology. 2010;52:436-42.
    PubMed     Text format     Related articles    Abstract available



  219. LEUTSCHER PD , Lagging M, Buhl MR, Pedersen C, et al
    Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
    Hepatology. 2010;52:430-435.
    PubMed     Text format     Related articles    Abstract available



  220. MORIISHI K , Shoji I, Mori Y, Suzuki R, et al
    Involvement of PA28gamma in the propagation of hepatitis C virus.
    Hepatology. 2010;52:411-20.
    PubMed     Text format     Related articles    Abstract available



    July 2010
  221. GREBELY J , Petoumenos K, Hellard M, Matthews GV, et al
    Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  222. PETTA S , Amato M, Cabibi D, Camma C, et al
    Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  223. ROOMER R , Hansen BE, Janssen HL, de Knegt RJ, et al
    Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  224. NDONGO N , Berthillon P, Pradat P, Vieux C, et al
    Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  225. BRENNDORFER ED , Weiland M, Frelin L, Derk E, et al
    Anti-tumor necrosis factor alpha treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  226. MACHADO MV , Oliveira AG, Cortez-Pinto H
    Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors.
    Hepatology. 2010;52:71-8.
    PubMed     Text format     Related articles    Abstract available



  227. DE MOCHEL NS , Seronello S, Wang SH, Ito C, et al
    Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection.
    Hepatology. 2010;52:47-59.
    PubMed     Text format     Related articles    Abstract available



  228. LAM KD , Bacchetti P, Abbasi F, Ayala CE, et al
    Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: Impact of obesity and ethnicity.
    Hepatology. 2010;52:38-46.
    PubMed     Text format     Related articles    Abstract available



  229. CREMIEUX P
    Methodological issues in a meta-analysis.
    Hepatology. 2010;52:395-6.
    PubMed     Text format     Related articles   



  230. MONTES-CANO MA , Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, et al
    Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes.
    Hepatology. 2010;52:33-7.
    PubMed     Text format     Related articles    Abstract available



    June 2010
  231. BUTI M , Lurie Y, Zakharova NG, Blokhina NP, et al
    Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  232. POORDAD F , Lawitz E, Shiffman ML, Hassanein T, et al
    Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  233. THOMPSON AJ , Muir AJ, Sulkowski MS, Patel K, et al
    Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  234. TOHME RA , Holmberg SD
    Is sexual contact a major mode of hepatitis C virus transmission?
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  235. POCKROS PJ , Hamzeh FM, Martin P, Lentz E, et al
    Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  236. ARORA S , Kalishman S, Thornton K, Dion D, et al
    Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  237. RAMCHARRAN D , Wahed AS, Conjeevaram HS, Evans RW, et al
    Associations between serum lipids and hepatitis C antiviral treatment efficacy.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  238. RIDRUEJO E , Adrover R, Cocozzella D, Reggiardo MV, et al
    Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.
    Hepatology. 2010;51:2231.
    PubMed     Text format     Related articles   



  239. PURNAK T , Efe C, Beyazit Y, Ozaslan E, et al
    Metabolic syndrome and obesity as additional factors that determine clinical response in chronic hepatitis C.
    Hepatology. 2010;51:2229-30.
    PubMed     Text format     Related articles   



  240. WASMUTH HE , Weiskirchen R
    Personalized medicine in hepatitis C: from genome-wide association studies to clinical practice.
    Hepatology. 2010;51:2223-5.
    PubMed     Text format     Related articles   



  241. BANAUDHA K , Orenstein JM, Korolnek T, St Laurent GC 3rd, et al
    Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis.
    Hepatology. 2010;51:1922-32.
    PubMed     Text format     Related articles    Abstract available



  242. WAGONER J , Negash A, Kane OJ, Martinez LE, et al
    Multiple effects of silymarin on the hepatitis C virus lifecycle.
    Hepatology. 2010;51:1912-21.
    PubMed     Text format     Related articles    Abstract available



  243. STERLING RK
    Long-term effects of sustained virologic response on the development of esophageal varices in compensated cirrhosis: "is the bang worth the buck?".
    Hepatology. 2010;51:1891-3.
    PubMed     Text format     Related articles   



  244. SHEN L
    Vitamin D controls T cell activation: Implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



    May 2010
  245. PENG ZG , Fan B, Du NN, Wang YP, et al
    Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  246. CRUZ AC , Engelson E, Ionescu G, Dubrovskaya V, et al
    Hepatitis C treatment in an urban population.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  247. MUIR AJ , Shiffman ML, Zaman A, Yoffe B, et al
    Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  248. MORGAN TR , Ghany MG, Kim HY, Snow KK, et al
    Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  249. HUNG CH , Lee CM, Lu SN, Wang JH, et al
    Hepatic steatosis with hepatitis B virus/hepatitis C virus dual infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  250. DAI CY , Huang CF, Huang JF, Chuang WL, et al
    Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
    Hepatology. 2010;51:1861-2.
    PubMed     Text format     Related articles   



  251. ALTINBAS A , Coban S, Yuksel O
    Fibrosis in liver as a predictive marker for hepatitis C virus therapy.
    Hepatology. 2010;51:1858.
    PubMed     Text format     Related articles   



  252. EYRE NS , Beard MR
    Hepatitis C virus infection in living color.
    Hepatology. 2010;51:1852-5.
    PubMed     Text format     Related articles   



  253. FINN RS
    Drug therapy: sorafenib.
    Hepatology. 2010;51:1843-9.
    PubMed     Text format     Related articles   



  254. STARLEY BQ , Calcagno CJ, Harrison SA
    Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Hepatology. 2010;51:1820-32.
    PubMed     Text format     Related articles    Abstract available



  255. ZEIN CO
    Clearing the smoke in chronic liver diseases.
    Hepatology. 2010;51:1487-90.
    PubMed     Text format     Related articles   



  256. ASKARIEH G , Alsio A, Pugnale P, Negro F, et al
    Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
    Hepatology. 2010;51:1523-30.
    PubMed     Text format     Related articles    Abstract available



    April 2010
  257. PFEFFER S , Baumert TF
    Antagonizing microRNA-122 and treatment of hepatitis C virus infection.
    Hepatology. 2010;51:1461-3.
    PubMed     Text format     Related articles   



  258. AWAD T , Thorlund K, Hauser G, Stimac D, et al
    Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
    Hepatology. 2010;51:1176-84.
    PubMed     Text format     Related articles    Abstract available



  259. ZALDIVAR MM , Pauels K, von Hundelshausen P, Berres ML, et al
    CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis.
    Hepatology. 2010;51:1345-53.
    PubMed     Text format     Related articles    Abstract available



    March 2010
  260. AKUTA N , Suzuki F, Hirakawa M, Kawamura Y, et al
    Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  261. PAWLOTSKY JM , Chevaliez S
    Preventing hepatitis C virus recurrence in liver transplant recipients: A role for adoptive immunotherapy?
    Hepatology. 2010;51:1072-1076.
    PubMed     Text format     Related articles   



    February 2010
  262. MITCHELL AE , Colvin HM, Palmer Beasley R
    Institute of Medicine recommendations for the prevention and control of hepatitis B and C.
    Hepatology. 2010;51:729-733.
    PubMed     Text format     Related articles    Abstract available



  263. LI JH , Qian Lao X, Tillmann HL, Rowell J, et al
    Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  264. HALFON P , Martinot-Peignoux M, Khiri H, Marcellin P, et al
    Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  265. SANYAL AJ
    The Institute of Medicine report on viral hepatitis: A call to action.
    Hepatology. 2010;51:727-728.
    PubMed     Text format     Related articles   



    January 2010
  266. WANG CC , Kao JH
    Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers.
    Hepatology. 2010;51:1082.
    PubMed     Text format     Related articles   



  267. PALENZUELA L , Mas A, Montaner J, Cordoba J, et al
    Matrix metalloproteinase-9 in fulminant hepatic failure.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  268. BONKOVSKY HL , Lambrecht RW, Naishadham D
    Genetic variations in heme oxygenase-1 and chronic hepatitis.
    Hepatology. 2010.
    PubMed     Text format     Related articles   



  269. BRUNO S , Crosignani A, Facciotto C, Rossi S, et al
    Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class a hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  270. DIAGO M , Shiffman ML, Bronowicki JP, Zeuzem S, et al
    Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  271. ASCHA MS , Hanouneh IA, Lopez R, Tamimi TA, et al
    The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Hepatology. 2010.
    PubMed     Text format     Related articles    Abstract available



  272. TERRAULT N , Khalili M
    A glimpse of future hepatitis C virus treatment paradigms.
    Hepatology. 2010;51:707-710.
    PubMed     Text format     Related articles   



  273. SHACKEL NA , Bowen DG, McCaughan GW
    Snipping away at hepatitis C.
    Hepatology. 2010;51:703-705.
    PubMed     Text format     Related articles   



    December 2009
  274. KUNIHOLM MH , Kovacs A, Gao X, Xue X, et al
    Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



  275. AIT-GOUGHOULTE M , Banerjee A, Meyer K, Mazumdar B, et al
    Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



  276. PETTA S , Camma C, Scazzone C, Tripodo C, et al
    Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



    November 2009
  277. MARTINOT-PEIGNOUX M , Stern C, Maylin S, Ripault MP, et al
    Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



  278. KRIEGER SE , Zeisel MB, Davis C, Thumann C, et al
    Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



  279. KNAPP S , Warshow U, Hegazy D, Brackenbury L, et al
    Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



  280. BINI EJ , Perumalswami PV
    Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



    October 2009
  281. HOU W , Tian Q, Zheng J, Bonkovsky HL, et al
    MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins.
    Hepatology. 2009.
    PubMed     Text format     Related articles    Abstract available



    September 2009
  282. EVERHART JE , Wright EC, Goodman ZD, Dienstag JL, et al
    Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Hepatology. 2009;51:585-594.
    PubMed     Text format     Related articles    Abstract available



  283. MODI AA , Feld JJ, Park Y, Kleiner DE, et al
    Increased caffeine consumption is associated with reduced hepatic fibrosis.
    Hepatology. 2009;51:201-209.
    PubMed     Text format     Related articles    Abstract available



Thank you for your interest in scientific medicine.


This service is provided by AMEDEO through an unrestricted educational grant from F. Hoffmann-La Roche.

Amedeo is a Flying Publisher website.

   Design: